At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 94 enrolled
Drug / intervention
GS-248 +1 moredrug
Likely dose
GS-248 120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomized, Multi-center, Placebo-controlled, Double-blind Study to Investigate the Safety of GS-248, and Efficacy on Raynaud's Phenomenon (RP) and Peripheral Vascular Blood Flow, in Subjects With Systemic Sclerosis (SSc)
In Brief
A Phase 2 clinical trial evaluating GS-248 and Placebo for Systemic Sclerosis. Completed, enrolled 94 participants across 12 sites in 4 countries.
Detailed Summary
The primary objective of this study is to determine the safety, and evaluate the efficacy of GS-248 versus placebo on Raynaud's Phenomenon (RP) in subjects with Systemic Sclerosis (SSc).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSystemic Sclerosis
CountriesBelgium, Netherlands, Poland, United Kingdom
CollaboratorsErgomed
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartDec 2020
First PostedFeb 2021
Primary CompletionJun 2022
TodayJul 2026
First PostedFeb 8, 2021
Enrollment StartDec 29, 2020
Primary CompletionJun 15, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 5.4 years ago
Interventions
GS-248drug
120 mg, capsule, once daily for 4 weeks
Placebodrug
capsule, once daily for 4 weeks